AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03387098
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione
Trial: NCT03387098
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
Trial: NCT03345316
Drug: FFI-1010
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous single dosing
Trial: NCT02740634
Drug: F-18 AV 1451
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tau binding agent
Trial: NCT02875314
Drug: Induction
RxNorm normalized name: Intravenous induction agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vincristine, cisplatin, cyclophosphamide, etoposide, high-dose methotrexate
Trial: NCT02875314
Drug: Single Cycle Intensive Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin, thiotepa, etoposide
Trial: NCT04041609
Drug: LYR-210
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single administration of LYR-210 depot
Trial: NCT04498923
Drug: Bupivacaine, dexamethasone, epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 75 mg, dexamethasone 4 mg, epinephrine 0,18 mg
Trial: NCT00016926
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02068027
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02048969
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A priming dose bolus of 0.4 mg of placebo will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of placebo mixed with saline will be administered to the patient at a rate of 0.1 mg per minute for a total of 7 doses during the scan. Total dose will be 1.0 mg.
Trial: NCT00494299
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: matching placebo
Trial: NCT00113087
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo
Trial: NCT01222624
Drug: PankoMab-GEX™
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03212690
Drug: Local standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local standard of care will include fluid resuscitation, use of vasopressor drugs and renal support.
Trial: NCT02350569
Drug: LDV/SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90/400 mg FDC tablet administered orally
Trial: NCT02654847
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02654847
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride solution, used as a diluent.
Trial: NCT03500848
Drug: MMF and/or steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For patients in both groups, MMF and/or steroids are initiated at or prior to the time of liver transplantation according to local practice. Steroids reduction is encouraged by 3 months post liver transplantation.
Trial: NCT00456157
Drug: Intra-articular Injection of OP-1 to affected knee
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03505190
Drug: RO7062931
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7062931 will be administered SC in single ascending doses with starting of 0.3 mg/kg and subsequent doses of 1.0 mg/kg, 2.0 mg/kg and 3.0 mg/kg, respectively. Additional (optional) dose of 4.0 mg/kg may be administered based on safety, tolerability and PK data.
Trial: NCT03505190
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered subcutaneously (SC).
Trial: NCT00202449
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01141452
Drug: Extra-fine hydrofluoroalkane beclomethasone MDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step-up in baseline BDP-equivalent ICS dose
Trial: NCT01141452
Drug: Chlorofluorocarbon beclomethasone metered dose inhaler
RxNorm normalized name: beclomethasone Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step-up in baseline BDP-equivalent ICS dose
Trial: NCT01141452
Drug: Hydrofluoroalkane beclomethasone metred dose inhaler
RxNorm normalized name: beclomethasone Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiation of ICS therapy
Trial: NCT00002532
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002532
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002532
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01634061
Drug: BEZ235
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEZ235 will be supplied as 50mg, 100mg, 200mg, 300mg and 400mg SDS sachets. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
Trial: NCT01634061
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BKM120 will be supplied as 10mg and 50mg hard gelatin capsules. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
Trial: NCT03904732
Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-dose acetylsalicylic acid, Aspirin (75-150 mg)
Trial: NCT01330784
Drug: hMG-HP
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03202836
Drug: Tocolytics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tocolysis for 48 hours
Trial: NCT03202836
Drug: Steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antenatal corticosteroids for 48 hours
Trial: NCT00860288
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02515396
Drug: MMI-0100
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02515396
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03015857
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: - norepinephrine; a vasopressor drug given to prevent post spinal hypotension
Trial: NCT04443530
Drug: Ultimaster™ Tansei™ stents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receiving Ultimaster™ Tansei™ stents
Trial: NCT04442906
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Group BF received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 fentanyl (50 ug)
Trial: NCT03015857
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intrathecal fentanyl 20 mcg will be given in both groups
Trial: NCT04108234
Drug: HR071603
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HR071603 monotherapy ,nasal spray
Trial: NCT04108234
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo,nasal spray
Trial: NCT02925117
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT00651391
Drug: Ezetimibe + Simvastatin
RxNorm normalized name: ezetimibe / simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet of ezetimibe 10 mg plus simvastatin 20 mg once daily in the evening for 12 weeks
Trial: NCT00651391
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral simvastatin 20 mg once daily in the evening for 12 weeks
Trial: NCT00651391
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo once daily in the evening for 12 weeks
Trial: NCT02007148
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: twice a day
Trial: NCT02267057
Drug: Paracetamol placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol placebo tablets produced by Kragerø tablettproduksjon.
Trial: NCT03265899
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray, 5 puffs balanced across nostrils, at an inter-puff interval of 30 seconds
Trial: NCT02145975
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The nurse will administer 1 ug per kg during 5 seconds when the patient complain of pain (visual analog scale, VAS, ≥7). Immediately with the onset of drug administration a timer started; every 5 minutes the researcher assess the EVA and the drug will be administered if VAS \> 3, until the patient manifests as a lower pain VAS ≤ 3 (mild). The nurse in charge in the PACU will manage the drug and will take 100 ug of fentanyl which is diluted in 10 mL of normal saline leaving a 10μg per ml concentration, are not labeled and for the physical and chemical characteristics of both drugs (colorless) risks of unblinded is minimized.
Trial: NCT00582036
Drug: Regular Insulin
RxNorm normalized name: Regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of sliding scale insulin as per Appendix 1
Trial: NCT04561128
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be subcutaneously administered with different dose levels
Trial: NCT01596647
Drug: caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
Trial: NCT01596647
Drug: diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
Trial: NCT01596647
Drug: TKI258
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dovitinib, 5 days on / 2 days off dose schedule
Trial: NCT03398044
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered to patients randomised into the control group arm.
Trial: NCT03506789
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline
Trial: NCT02784106
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received placebo matched to M2951 twice daily up to Day 84 during the double-blind treatment period.
Trial: NCT03332329
Drug: Granulocyte Macrophage Colony Stimulating Factor
RxNorm normalized name: Granulocyte macrophage colony stimulating factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte-macrophage colony stimulating factor is used intermittently from baseline to week 16 and from 60 to week 84
Trial: NCT03332329
Drug: HBV vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60ug HBV vaccine is used every four week for 24 weeks
Trial: NCT01989520
Drug: Phase IIb formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose 45mg AZD5069
Trial: NCT01989520
Drug: Putative phase III formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose 45mg AZD5069
Trial: NCT01989520
Drug: Test treatment E
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet formulation E, 45 mg (intermediate dissolution variant) of AZD5069
Trial: NCT00181155
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion of 50 ml dose of 5% dextrose
Trial: NCT01697722
Drug: Extra-fine hydrofluoroalkane-beclometasone dipropionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase in the baseline BDP-equivalent dose of inhaled corticosteroid as HFA-BDP via pMDI or BAI
Trial: NCT03635853
Drug: drug containing extract from cock's comb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a container containing 25 mg of ointment having extract from cock's comb as active ingredient two times daily for 3 months
Trial: NCT02260557
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching selexipag 200 μg tablets to be administered orally twice daily
Trial: NCT01548287
Drug: AZD5213
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5213 doseA daily
Trial: NCT03651674
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients only have antipsychotic drugs
Trial: NCT01548287
Drug: AZD5213
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5213 doseB daily
Trial: NCT01548287
Drug: AZD5213
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5213 doseC daily
Trial: NCT00841256
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was given in the same way as the sublingual active treatment. Symptomatic standard treatment, i.e. antihistamines and glucocorticoids as well as alphamimetics is allowed during grass pollen season.
Trial: NCT02959905
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 500 mg/m2/day iv on day -5 for one day.
Trial: NCT02959905
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 500 mg/m2/day iv on day -5 and -4 for two days.
Trial: NCT04164888
Drug: CIVI 007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hypercholesterolemia agent
Trial: NCT04098874
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 weeks postpartum of blinded placebo
Trial: NCT01080742
Drug: Lodoz (Combination of bisoprolol and hydrochlorothiazide)
RxNorm normalized name: caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The investigator will decide in advance the best therapeutic strategy for each subject according to current practice, regardless of the potential participation of this subject in the study.
Trial: NCT04045665
Drug: Antiplatelet-only strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 75-325 mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)
Trial: NCT04045665
Drug: Oral Anticoagulant plus background antiplatelet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC with vitamin K antagonist (VKA) with international normalized ratio (INR) target 2-3 or any approved direct oral anticoagulant OR apixaban, rivaroxaban, edoxaban or dabigatran) in addition to background antiplatelet therapy with aspirin 75-325mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)
Trial: NCT00809042
Drug: L-carnitine and hydroxyurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). L-carnitine (Minoo, Iran, 250 mg tablets) was administered in divided doses (50mg/kg/day).
Trial: NCT00809042
Drug: hydroxyurea and magnesium chloride
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). Magnesium chloride powder ( tabib tajhiz nik, Iran) was formulated into suspension; each ml containing 1meq magnesium chloride. It was administered in divided doses at 0.6meq/kg/day.
Trial: NCT00809042
Drug: hydroxyurea,L-carnitine and magnesium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). L-carnitine (Minoo, Iran, 250 mg tablets) was administered in divided doses (50mg/kg/day). Magnesium chloride powder ( tabib tajhiz nik, Iran) was formulated into suspension; each ml containing 1meq magnesium chloride. It was administered in divided doses at 0.6meq/kg/day
Trial: NCT01349556
Drug: Tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tretinoin 0.025% cream
Trial: NCT02901925
Drug: ABY-029
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using a sample size of 6-12 patients, ABY-029 will be administered via single intravenous injection to subjects with recurrent glioma, approximately 1-3 hours prior to surgery. Microdose levels of ABY-029 have been selected to determine if a fluorescence signal can be detected by wide-field imaging technology with a signal-to-noise ratio of 10, which is considered necessary for subsequent assessment of diagnostic performance of ABY-029 as a tumor biomarker sufficient to guide surgical resection in the future. Administration of the study drug is not intended to alter the extent of planned brain tumor resection during the surgical procedure.
Trial: NCT00238173
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: (330 mg/m2/day; total dose 660 mg/m2) will be infused i.v. in 25-50 cc of normal saline, over approximately 10 minutes.
Trial: NCT00239538
Drug: telmisartan combined with hydrochlorothiazide (80/12.5 mg)
RxNorm normalized name: hydrochlorothiazide / telmisartan
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00239538
Drug: valsartan combined with hydrochlorothiazide (160/12.5mg)
RxNorm normalized name: hydrochlorothiazide / valsartan
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02515448
Drug: gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00526409
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction: 60 mg/m2/day, oral or i.v x 21 days and 30 mg/m2/day oral or iv x 7 days Reinduction-Intensification Treatment: 60 mg/m2/d x 14 days and 30 mg/m2/day oral x 7 days
Trial: NCT00526409
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction: 500 mg/m2 iv, days 1, 2, 29 Consolidation (Bloc I): 500 mg/m2 iv, day 8 Reinduction:500 mg/m2 iv, day 15
Trial: NCT00526409
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Consolidation (Bloc I): 5 g/m2 24 hours infusion Consolidation (Bloc II): 5 g/m2 24 hours infusion Reinduction: 3 g/m2 24 hours infusion Maintenance: 20 mg/m2/d, IM/week x 3 (1, 7, 14)
Trial: NCT00414271
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 900 mg/m2 PO two times per day from day 1 to day 14 every 3 weeks for 2 cycles.
Trial: NCT01623622
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once or more / week
Trial: NCT02603952
Drug: MEDI8852
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) administered as a single IV infusion of 750 mg or 3000 mg on Day 1.
Trial: NCT02629549
Drug: OTL38
RxNorm normalized name: Fluorodeoxyglucose F 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of OTL38 prior to surgery
Trial: NCT00531934
Drug: Doxycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg po daily
Trial: NCT00626704
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of Daunorubicin.
Trial: NCT04616196
Drug: NKTR-255
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NKTR-255 IV every 21 days
Trial: NCT00540657
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule, twice daily, 13 weeks
Trial: NCT00429806
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03830528
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All study cohorts (except Part C) are placebo controlled.
Trial: NCT02127996
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline
Trial: NCT02184273
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03519178
Drug: Endocrine Therapy 1
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endocrine Therapy 1
Trial: NCT03519178
Drug: Endocrine Therapy 2
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endocrine Therapy 2
Trial: NCT03561506
Drug: 0.9% Normal Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo(0.9% Normal Saline) to be administered as IV drip infusion or bolus injection to consented patients with preoperative anemia before total knee arthroplasty.
Trial: NCT00858195
Drug: Indomethacin 75mg Extended-Release Capsules, Sandoz
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00858195
Drug: Indocin 75mg SR Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00306748
Drug: MD-1100 Acetate
FDA approved: no
EMA approved: no
PMDA approved: no